Ropivacaine mitigates neuropathic pain by inhibiting the activation of the TRAF2/PI3K/Akt/NF-κB signaling pathway.

ABSTRACT: Neuroinflammation is central to neuropathic pain pathogenesis. While ropivacaine demonstrates anti-neuroinflammatory effects through NF-κB pathway suppression, its mechanistic link to analgesia remains unclear. This study investigates ropivacaine's neuromodulatory role in neuroinflammatory responses during pain progression, specifically targeting NF-κB signaling. Our findings reveal how ropivacaine alleviates neuropathic pain by inhibiting this pathway, offering critical insights into its therapeutic potential via neuroinflammatory modulation. The spared nerve injury (SNI) model was established in rats according to standardized protocols. Ropivacaine was administered intrathecally daily for 7 days after SNI surgery. Behavioral Assessment: Paw Withdrawal Mechanical Threshold (PWMT) was quan

SUBMITTER: Zhang L 

PROVIDER: S-EPMC12474919 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature